Citations

Showing 10 of 108083 citations.

The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
Shi, Qian , Flowers, Christopher R. , Schmitz, Norbert , Flament, Jocelyne, Coiffier, Bertrand , group, on behalf of the SEAL, Shi, Qian , Sargent, Daniel J. , Habermann, Thomas M. , Fu, Tommy , group, on behalf of the SEAL

Mayo Clinic

The Oncologist | August 11, 2017 | Volume: 22 | Issue: 12 | Pages: 1415-1418

10.1634/theoncologist.2017-0177 | PMID 28798271 Get It

This commentary describes the progress of the SEAL [Surrogate Endpoints for Aggressive Lymphoma] research group and invites collaboration in sharing data to continue building a large database of individual patient data from multiple clinical trials in DLBCL.
Author response: Unexpected sequences and structures of mtDNA required for efficient transcription from the first heavy-strand promoter
Uchida, Akira , Murugesapillai, Divakaran , Wang, Yao , Lodeiro, María F. , Prabhakar, Shaan, Oliver, Guinevere V , Arnold, Jamie J. , Maher, L. James, Cameron, Craig E. , Kastner, Markus , Williams, Mark C.

Mayo Clinic

No container title available | August 10, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.27283.032 Get It

Incidence of First-Time Lateral Patellar Dislocation: A 21-Year Population-Based Study
Sanders, Thomas L. , Pareek, Ayoosh , Hewett, Timothy E. , Dahm, Diane L., Krych, Aaron J. , Krych, Aaron J , Stuart, Michael J.

Mayo Clinic

Sports Health: A Multidisciplinary Approach | August 10, 2017 | Volume: 10 | Issue: 2 | Pages: 146-151

10.1177/1941738117725055 | PMID 28795924 Get It

Background: First-time lateral patellar dislocation is a common orthopaedic injury. The purposes of this study were to (1) evaluate the incidence of first-time lateral patellar dislocation in a geographically-determined population, (2) report trends over time in the incidence of dislocation, and (3) describe the rate of surgical treatment. Hypothesis: The rate of patellar dislocation is highest among adolescent patients. Study Design: Cohort study. Level of Evidence: Level 3. Methods: The study population included 609 individuals identified through a multidisciplinary geographic cohort county database who were diagnosed with first-episode lateral patellar dislocation between 1990 and 2010. The complete medical records were reviewed to confirm the diagnosis and to evaluate details of injury and treatment. Age- and sex-specific incidence rates were calculated and adjusted to the 2010 US population. Poisson regression analyses were performed to examine incidence trends by age, sex, and calendar period. Results: The overall age- and sex-adjusted annual incidence of patellar dislocation was 23.2 (95% CI, 21.2-24.9) per 100,000 person-years. The annual incidence was similar between male and female patients and highest among adolescents aged 14 to 18 years (147.7/100,000 person-years). The mean age at dislocation was 21.4 ± 9.9 years, and 331 patients (54.4%) were female. During the study period, there was a significant decline in the incidence of patellar dislocation among men aged 19 to 25 years ( P = 0.002) and girls aged 14 to 18 years ( P = 0.025). Eighty patients received surgical treatment during the study period, including 66 patients (10.8%) for recurrent instability and 14 patients (2.3%) for acute osteochondral injury. Conclusion: With an annual incidence of 23.2 per 100,000 person-years, lateral patellar dislocation is a frequently encountered orthopaedic injury. The incidence of dislocation among adolescent patients in this cohort is higher than previously reported. Despite a decrease in the annual incidence of dislocation in adolescent girls, the overall incidence of patellar dislocation remained relatively constant over a 21-year observation period. Clinical Relevance: This study demonstrates that the incidence of patellar dislocation in adolescents is greater than previously reported.
Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5
Nguyen, Tien, Barry, Mary , Turner, Mallory, Crosby, Catherine, Trujillo, Miguel, Morris, John, Barry, Michael, Barry, Michael A. , Turner, Mallory A., Crosby, Catherine M. , Trujillo, Miguel A., Barry, Michael A

Mayo Clinic

Biomedicines | August 10, 2017 | Volume: 5 | Issue: 3 | Pages: 46

10.3390/biomedicines5030046 | PMID 28796161 Get It

Oncolytic viruses would ideally be of use for systemic therapy to treat disseminated cancer. To do this safely, this may require multiple layers of cancer specificity. The pharmacology and specificity of oncolytic adenoviruses can be modified by (1) physical retargeting, (2) physical detargeting, (3) chemical shielding, or (4) by modifying the ability of viral early gene products to selectively activate in cancer versus normal cells. We explored the utility of these approaches with oncolytic adenovirus serotype 5 (Ad5) in immunocompetent Syrian hamsters bearing subcutaneous HaK tumors. After a single intravenous injection to reach the distant tumors, the physically hepatocyte-detargeted virus Ad5-hexon-BAP was more effective than conditionally replicating Ad5-dl1101/07 with mutations in its E1A protein. When these control or Ad5 treated animals were treated a second time by intratumoral injection, prior exposure to Ad5 did not affect tumor growth, suggesting that anti-Ad immunity neither prevented treatment nor amplified anti-tumor immune responses. Ad5-dl1101/07 was next chemically shielded with polyethylene glycol (PEG). While 5 kDa of PEG blunted pro-inflammatory IL-6 production induced by Ad5-dl1101/07, this shielding reduced Ad oncolytic activity.
In Vivo Ambient Serotonin Measurements at Carbon-Fiber Microelectrodes
Abdalla, Aya , Atcherley, Christopher W., Pathirathna, Pavithra , Samaranayake, Srimal, Qiang, Beidi , Peña, Edsel A. , Heien, Michael L. , Hashemi, Parastoo , Heien, Michael L , Hashemi, Parastoo , Morgan, Stephen L.

Mayo Clinic

Analytical Chemistry | August 10, 2017 | Volume: 89 | Issue: 18 | Pages: 9703-9711

10.1021/acs.analchem.7b01257 | PMID 28795565 Get It

The History of Enhanced Recovery After Surgery and the ERAS Society
Ljungqvist, Olle , Young‐Fadok, Tonia M., Demartines, Nicolas , Young-Fadok, Tonia, Demartines, N

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | August 10, 2017 | Volume: 27 | Issue: 9 | Pages: 860-862

10.1089/lap.2017.0350 | PMID 28795858 Get It

Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching*
Trauer, James M. , Muhi, Stephen , McBryde, Emma S. , Harbi, Shmeylan Al, Arabi, Yaseen M. , Boyle, Andrew , Cartin‐Ceba, Rodrigo , Chen, Yung‐Tai , Gajić, Ognjen, Godsell, Jack , Gong, Michelle N. , Kor, Daryl J. , Lösche, Wolfgang, McAuley, Daniel F. , O’Neal, Hollis R. , Otto, Gordon P , Soßdorf, Maik, Tsai, Min-Juei, Valerio-Rojas, Juan Carlos , Poll, Tom van der , Ware, Lorraine B. , Widmer, Andreas F. , Wiewel, Maryse A. , Winning, Johannes, Eisen, Damon P. , Trauer, James, Harbi, Shmeylan A. Al , Chen, Wei, Falcone, Marco , Gajic, Ognjen , Osthoff, Michael Friedrich , Violi, Francesco , Arabi, Yaseen M

Mayo Clinic

Critical Care Medicine | August 10, 2017 | Volume: 45 | Issue: 11 | Pages: 1871-1879

10.1097/ccm.0000000000002654 | PMID 28799949 Get It

Objective: The primary objective was to conduct a meta-analysis on published observational cohort data describing the association between acetyl-salicylic acid (aspirin) use prior to the onset of sepsis and mortality in hospitalized patients. Study Selection: Studies that reported mortality in patients on aspirin with sepsis with a comparison group of patients with sepsis not on prior aspirin therapy were included. Data Sources: Fifteen studies described hospital-based cohorts (n = 17,065), whereas one was a large insurance-based database (n = 683,421). Individual-level patient data were incorporated from all selected studies. Data Extraction: Propensity analyses with 1:1 propensity score matching at the study level were performed, using the most consistently available covariates judged to be associated with aspirin. Meta-analyses were performed to estimate the pooled average treatment effect of aspirin on sepsis-related mortality. Data Synthesis: Use of aspirin was associated with a 7% (95% CI, 2–12%; p = 0.005) reduction in the risk of death as shown by meta-analysis with considerable statistical heterogeneity (I 2 = 61.6%). Conclusions: These results are consistent with effects ranging from a 2% to 12% reduction in mortality risk in patients taking aspirin prior to sepsis onset. This association anticipates results of definitive studies of the use of low-dose aspirin as a strategy for reduction of deaths in patients with sepsis.
Angiographic classification of patterns of restenosis following femoropopliteal artery intervention: A proposed scoring system
Garcia, Lawrence A., Rocha‐Singh, Krishna J. , Krishnan, Prakash , Tepe, Gunnar , Granada, Juan F. , Turco, Mark, Tieché, Christopher, Fleming, Mark, Granada, Juan F , Zeller, Thomas , Fleming, Mark D. , Jaff, Michael R.

Mayo Clinic

Catheterization and Cardiovascular Interventions | August 10, 2017 | Volume: 90 | Issue: 4 | Pages: 639-646

10.1002/ccd.27198 | PMID 28795488 Get It

AbstractObjectivesTo propose a classification system for characterizing angiographic femoropopliteal artery restenosis patterns associated with common endovascular modalities.BackgroundPeripheral artery disease is a worldwide issue affecting millions of people. Despite a myriad of endovascular technologies available to treat peripheral artery disease of the femoropopliteal arteries, restenosis remains a common failure mode. Characterizing common patterns of restenosis is important to discern the potential impact of baseline patient, lesion, and procedural characteristics, as well as treatment modalities on either the primary success or the failure patterns associated with restenosis.MethodsStudies included in the analysis were from previous core laboratory‐adjudicated femoropopliteal artery disease trials and registries reflecting a wide array of treatment modalities.ResultsFrom the subjects enrolled and analyzed, there were 403 total angiograms for analysis and adjudication. Target lesion revascularization images of the 32 validation cases were evaluated for index treated length, diameter stenosis, and lesion morphology characteristics. The following lesion types are proposed: Type 1 “Focal” pattern, which may be “Edge Proximal” or “Edge Distal” depending on location; a Type 2 “Multifocal” pattern which may also exhibit edge restenosis, but may also be “Edge Bilateral”; a Type 3 “Moderate” pattern and a Type 4 “Diffuse” pattern; and finally, a Type 5 “Occlusion”.ConclusionsA classification system that enables healthcare professionals to anticipate and describe failures following the index procedure, thereby impacting the choice of options for retreatment, may facilitate consistency and standardization within the heterogeneous field of endovascular device treatments for the femoropopliteal artery.
Hospital teaching status and trascatheter aortic valve replacement outcomes in the United States: Analysis of the national inpatient sample
Telila, Tesfaye , Akintoye, Emmanuel , Ando, Tomo , Merid, Obsinet, Palla, Mohan, Mallikethi‐Reddy, Sagar , Briasoulis, Αlexandros , Afonso, Luis , Briasoulis, Alexandros, Briasoulis, Alexandros , Mallikethi‐Reddy, Sagar , Grines, Cindy L.

Mayo Clinic

Catheterization and Cardiovascular Interventions | August 10, 2017 | Volume: 90 | Issue: 7 | Pages: 1200-1205

10.1002/ccd.27236 | PMID 28795480 Get It

AbstractBackgroundEvidence suggests that medical service offerings vary by hospital teaching status. However, little is known about how these translate to patient outcomes. We therefore sought to evaluate this gap in knowledge in patients undergoing Transcatheter aortic valve replacement (TAVR) in the United States.MethodsThis study was conducted using the National Inpatient Sample (NIS) in the United States from 2011 to 2014. Teaching status was classified, as teaching vs. nonteaching and endpoints were clinical outcomes, length of stay and cost. Procedure‐related complications were identified via ICD‐9 coding and analysis was performed via mixed effect model.ResultsAn estimated 33,790 TAVR procedures were performed in the U.S between 2011 and 2014, out of which 89.3% were in teaching hospitals. Mean (SD) age was 81.4 (8.5) and 47% were females. There was no significant difference between teaching versus nonteaching hospitals in regards to the primary outcome of in‐hospital mortality and secondary outcomes of several cardiovascular and other end points except for a high rates of acute kidney injury (AKI) (OR: 1.34 [95% CI, 1.04–1.72]) and lower rate for use of mechanical circulatory support devices in teaching vs. nonteaching centers. The mean length of stay was significantly higher in teaching hospitals (7.7 days) vs. nonteaching hospitals (6.8 days) (P = 0.002) and so was the median cost of hospitalization (USD 50,814 vs. USD 48, 787, P = 0.02) for teaching vs. nonteaching centers.ConclusionMost TAVR related short‐term outcomes including all cause in‐hospital mortality are about the same in teaching and nonteaching hospitals. However, AKI, length of hospital stay and TAVR related cost were significantly higher in teaching than nonteaching hospitals. There was more use of mechanical circulatory support in nonteaching than teaching hospitals.
Gender and survival in essential thrombocythemia: A two‐center study of 1,494 patients
Tefferi, Ayalew , Betti, Silvia, Barraco, Daniela , Mudireddy, Mythri , Shah, Sahrish, Hanson, Curtis A. , Ketterling, Rhett P. , Pardanani, Animesh , Gangat, Naseema , Coltro, Giacomo , Ketterling, Rhett P , Betti, Silvia, Guglielmelli, Paola , Vannucchi, Alessandro M.

Mayo Clinic

American Journal of Hematology | August 10, 2017 | Volume: 92 | Issue: 11 | Pages: 1193-1197

10.1002/ajh.24882 | PMID 28795425 Get It

Abstract Based on suggestive information from recent epidemiologic data and earlier retrospective studies, we revisited the effect of gender on survival in 1,494 patients with essential thrombocythemia (ET). The primary study population included 904 patients from the Mayo Clinic (median age 58 years; 65% females); risk distribution, according to the international prognostic score for ET (IPSET), was 23% high, 42% intermediate and 35% low. Multivariable analysis that included IPSET‐relevant risk factors identified male sex (HR 1.6, 95% CI 1.3‐2.0), age ≥60 years (HR 4.3, 95% CI 3.4‐5.4) and leukocyte count ≥11 × 10(9)/L (HR 1.5, 95% CI 1.3‐1.9) as independent predictors of shortened survival. These findings were confirmed by analysis of a separate cohort of 590 ET patients (65% females) from the University of Florence, Italy, with corresponding HRs (95% CI) of 1.6 (1.1‐2.5), 4.6 (2.2‐9.5) and 1.8 (1.1‐2.8). The independent prognostic effect of gender was further corroborated by a separate multivariable analysis against IPSET risk categories; HR (95% CI) for the Mayo Clinic/Florence cohorts were 1.5/1.6 (1.2/1.1‐1.8/2.5) for male sex, 6.8/7.5 (5.0/3.1‐9.3/18.3) for IPSET high risk and 2.8/4.1 (2.1/1.8‐3.8/9.5) for IPSET intermediate risk. Furthermore, the survival disadvantage in men was most apparent in IPSET high risk category and in patients older than 60 years. In both patient cohorts, thrombosis history garnered significance in univariate, but not in multivariable analysis. The observations from the current study suggest that women with ET live longer than their male counterparts and that gender might supersede thrombosis history as a risk variable for overall survival.